Many traditional clinical assays lack the ability for electronic adaptation and timely results. The need exists for rapid, sensitive, and inexpensive methods that could be utilized in clinical settings [9] . Therefore, the rapid realtime quantification of a QCM has been combined with the selectivity of monoclonal antibodies to create an immunosensor for evaluation of the multifunctional nanoparticles. The use of a QCM for immunological detection has been demonstrated previously, where it has been shown to detect Staphylococcus epidermidis in clinical samples using nanoparticle amplification [10] , SARS virus in sputum samples [11] , plant pathogens [12] , an antigenic mimic of Ebola [5] , and influenza A and B from nasal washes [13] . In QCM assays, nanoparticles have enabled simultaneous parallel detection and amplification for gravimetry, thus lowering the limit of detection [6, [14] [15] [16] [17] . A QCM-based sensor with a nanoparticle control would allow for the simultaneous rapid and accurate analysis of multiple viral or biological hazards, without posing a safety or health threat. The work reported here builds on this previous work and addresses the specificity of detection of antibody-antigen binding at the QCM using polyepitope-functionalized gold nanoparticles.